Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy with or without famitinib for first-line advanced non-squamous NSCLC
ChiCTR2000037269Phase 3Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Oct 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of camrelizumab, famitinib, pemetrexed and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: progression-free survival. Started Oct 2020; status: recruiting.
02
Drugs
camrelizumabfamitinibpemetrexedcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000037269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037269.